Lantheus Holdings Research and Development Expenses 2013-2024 | LNTH

Lantheus Holdings research and development expenses for the twelve months ending September 30, 2024 were $0.150B, a 55.09% decline year-over-year.

  • Lantheus Holdings annual research and development expenses for 2023 were $0.078B, a 75.07% decline from 2022.
  • Lantheus Holdings annual research and development expenses for 2022 were $0.312B, a 593.15% increase from 2021.
  • Lantheus Holdings annual research and development expenses for 2021 were $0.045B, a 37.14% increase from 2020.

Lantheus Holdings Research and Development Expenses 2013-2024 | LNTH

  • Lantheus Holdings annual research and development expenses for 2023 were $0.078B, a 75.07% decline from 2022.
  • Lantheus Holdings annual research and development expenses for 2022 were $0.312B, a 593.15% increase from 2021.
  • Lantheus Holdings annual research and development expenses for 2021 were $0.045B, a 37.14% increase from 2020.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$203.2B
Stryker (SYK)$148.2B
Boston Scientific (BSX)$133.1B
EssilorLuxottica (ESLOY)$113.5B
Medtronic (MDT)$109B
Haleon (HLN)$42.9B
Lonza Group Ag (LZAGY)$42.1B
GE HealthCare Technologies (GEHC)$37.7B
ResMed (RMD)$35B
Terumo (TRUMY)$29.2B
Koninklijke Philips (PHG)$24.4B
Zimmer Biomet Holdings (ZBH)$22.1B
Insulet (PODD)$18.4B
Baxter (BAX)$16.6B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$9.5B
Bio-Rad Laboratories (BIO)$9B
Demant (WILYY)$8.3B
TG Therapeutics (TGTX)$4.7B
Haemonetics (HAE)$4.3B
ICU Medical (ICUI)$4.2B
Prestige Consumer Healthcare (PBH)$4.1B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.5B
Neogen (NEOG)$3.3B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.8B
QuidelOrtho (QDEL)$2.6B
Warby Parker (WRBY)$2.3B